Neurological complications and infection caused by the herpes simplex virus type 1 and 2

Types of patients: all patients with recurrent types of herpes simplex virus type 1 and 2 infections that damage skin and central neural system, the patients with confirmed neurological complications of herpes simplex virus type 1 and 2 .

Therapy principle: From 60 to 95% of the adult population is infected with herpes simplex virus 1 and/or 2. Labial form of infection is the most frequent and is also known as love blister. Herpes simplex virus of type1 can also damage the mucosa of a mouth, eyes, skin of the head, torso and limbs. Genital herpes rates the second by frequency and infects genital area predominantly. Herpes simplex virus infections present a serious medical and social problem and significantly interfere with normal life of the people. The available methods only suppress the expansion of the virus but do not remove the fragments of the viral DNA from the cells. Hence there is always the opportunity of the relapse. The treatment with antiviral drugs suppresses the activity of the virus that gradually develops tolerance to the given therapy and ceases to respond to it. The vaccines that are being developed rely on the formation of the antibody immunity and have failed to demonstrate their effectiveness during the clinical trials. The virus has the ability to persist in ganglia and to disseminate through nerve stems. Antibodies do not penetrate the nerve sheath and, accordingly, do not block viral activation. Successful immunological control can be achieved due to the specific activation of the personalised immunity.

Currently, it is only possible to obtain an individually tailored cell immune preparation against herpes simplex virus. At the first stage, the sample of the whole blood of the patient is isolated, or, alternatively, a mononuclear fraction of the WBCs of blood is isolated at the cell separator. The obtained blood cells are cultured in the laboratory to obtain antigen-representing dendritic cells that are further loaded with the antigens of herpes simplex virus. Antigen-presenting cells of the patient absorb the virus, digest it inside and bring the antigens that are necessary to form the personalised immune response out to the surface of the cell. The received immune preparation is frozen and stored at low temperatures to preserve its properties; it is administered to the patient threefold with specific intervals and the formation of the cell response of the immune system is controlled. The method to produce anti-herpetic personalized immune preparation is protected by the patent for invention of the Russian Federation 2514034, dated 14.08.2012. We have helped to over 80 patients with this method.

Result. The patients showed significantly improved condition after the treatment with full course of dendritic vaccine: 73% showed no relapses for three years and longer; 25% showed reduced number of relapses by 60-80% per years. Two per cent demonstrated no effect.